These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 436376)

  • 1. [Physiopathology and therapy of obliterating arteriopathies].
    Schettler G; Mörl H
    Clin Ter; 1979 Jan; 88(1):3-19. PubMed ID: 436376
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current trends in medical therapy of chronic peripheral obliterating arteriopathies].
    Peruzzi G; Tallarida G; Baldoni F; Raimondi G; Grimaldi I; Sangiorgi M
    Clin Ter; 1985 Jul; 114(1):3-26. PubMed ID: 2864161
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of papaveroline on chronic, obliterating, peripheral arterial diseases].
    Sironi G; Benedetti G
    Minerva Cardioangiol; 1973 Apr; 21(4):257-63. PubMed ID: 4710122
    [No Abstract]   [Full Text] [Related]  

  • 4. [Action and tolerability of delayed-action buflomedil in obliterating arteriopathies of the lower limbs. A multicenter study].
    Andreozzi GM; Lepore R
    Clin Ter; 1990 Nov; 135(4):273-81. PubMed ID: 2150026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experiences with Trental in peripheral circulatory disorders and cerebrovascular insufficiency (author's transl)].
    Schafé MK
    Munch Med Wochenschr; 1973 Oct; 115(40):1745-9. PubMed ID: 4801042
    [No Abstract]   [Full Text] [Related]  

  • 6. [The vasoactivogram in the treatment of peripheral arteriopathies].
    Romeo S; Spinella G; Sciacchitanto D
    Angiologia; 1975; 27(1):7-25. PubMed ID: 1111377
    [No Abstract]   [Full Text] [Related]  

  • 7. [Correlations between reactive hyperemia and response to vasodilator agents in patients with obliterating arteriopathies of the lower limbs].
    Dabizzi RP; Fantini F; Cappelli G; Grandonico F
    Minerva Cardioangiol; 1970 May; 18(5):287-90. PubMed ID: 5515012
    [No Abstract]   [Full Text] [Related]  

  • 8. [New data on vasoactive drug. Patients with peripheral arterial occlusive disease walk twice as long].
    MMW Fortschr Med; 2002 May; 144(21):54. PubMed ID: 12134429
    [No Abstract]   [Full Text] [Related]  

  • 9. Peripheral arterial disease: drug therapy.
    Schwartz JB
    J Gend Specif Med; 2002; 5(4):16-20. PubMed ID: 12192882
    [No Abstract]   [Full Text] [Related]  

  • 10. [Vasodilator drugs and obliterating arterial diseases of the lower extremities].
    Larsen OA; Lassen NA
    Ugeskr Laeger; 1967 Sep; 129(36):1168-71. PubMed ID: 5598859
    [No Abstract]   [Full Text] [Related]  

  • 11. [Shunt effect in iloprost treatment of obliterative arteriopathy].
    Vannucchi PL; Polignano R; Becucci P; Milli M
    Minerva Cardioangiol; 1999 Dec; 47(12):654-5. PubMed ID: 10670247
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparison of 2 effective doses of Fludilat in peripheral vascular disorders in a double-blind trial].
    König FK
    Med Welt; 1973 Sep; 24(39):1490-2. PubMed ID: 4588974
    [No Abstract]   [Full Text] [Related]  

  • 13. [Microcirculation in peripheral arterial occlusive diseases will improve. Prostaglandin can prevent surgery].
    MMW Fortschr Med; 2003 Dec; 145(51-52):41. PubMed ID: 14974333
    [No Abstract]   [Full Text] [Related]  

  • 14. [On the treatment of "intermittent claudication" in chronic peripheral obliterating arteriopathies of the lower extremities caused by arteriosclerosis and Buerger's disease].
    Seghezzi R; Pedroni G; Borri P
    Chir Ital; 1967; 19():Suppl 2:222+. PubMed ID: 5190600
    [No Abstract]   [Full Text] [Related]  

  • 15. [Buflomedil in arterial occlusive disease. Results of a controlled study].
    Trübestein G; Balzer K; Bisler H; Klüken N; Mahfoud Y; Müller-Wiefel H; Unkel B; Ziegler W
    Dtsch Med Wochenschr; 1982 Dec; 107(51-52):1957-61. PubMed ID: 6756854
    [No Abstract]   [Full Text] [Related]  

  • 16. [Medical treatment of obliterating arteriopathies of the lower limbs with vasoactive drugs].
    Raspanti D; Cameli AM; Trapani M; Dorigo D; Mazzotta A; Negro P
    Clin Ter; 1987 Jun; 121(6):479-83. PubMed ID: 2973884
    [No Abstract]   [Full Text] [Related]  

  • 17. Positive effect of oral buflomedil on exercise-induced haemorheological damage and on claudication distance in peripheral obliterative arterial disease patients.
    Forconi S; Pieragalli D; Acciavatti A; Del Bigo C; Galigani C; Ralli L; Guerrini M; Di Perri T
    J Int Med Res; 1984; 12(3):188-92. PubMed ID: 6734922
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current trends in medical treatment of obliterating arteriopathies of the limbs].
    Pratesi F; Caramelli L; Deidda C; Nuti A; Tesi M
    Recenti Prog Med; 1973 Aug; 55(2):163-90. PubMed ID: 4148951
    [No Abstract]   [Full Text] [Related]  

  • 19. General discussion on therapy in occlusive arterial disease.
    Scand J Clin Lab Invest Suppl; 1973; 128():223-7. PubMed ID: 4764587
    [No Abstract]   [Full Text] [Related]  

  • 20. [Intra-arterial infusion therapy in thrombo-obliterating diseases of the lower limbs].
    Kurbangaleev SM; Savel'ev IuS
    Vestn Khir Im I I Grek; 1974 Oct; 113(10):68-71. PubMed ID: 4432347
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.